Odevixibat (Bylvay) for Progressive Familial Intrahepatic Cholestasis-Associated Pruritus

Date: February 21, 2022 Issue #:  1644Summary:  Odevixibat (Bylvay– Albireo), an oral ileal bile acid transporter (IBAT) inhibitor, has been approved by the FDA for treatment of pruritus in patients ≥3 months old with progressive familial intrahepatic cholestasis (PFIC). It is the first drug to be approved in the US for this indication.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: Actigall Antihistamines Bylvay Naltrexone odevixibat Rifampin Urso ursodeoxycholic acid Ursodiol Source Type: research